Drug lookup | Fillwise

ALTRETAMINE

All products: general benefit

Other products in the same Health Canada class (L01X, L01XX) — coverage varies; not interchangeable

Hydroxyurea (Hydrea): general benefit
Mitotane (Lysodren): general benefit
Procarbazine (Matulane): general benefit

Hexalen · DIN 02126230 · 50mg · capsule

General benefit; Health Canada lists this DIN as Cancelled post market since 2013-09-09 — choose a marketed DIN from the same-category list.Discontinued 2013-09-09 · checked 2026-09-02

StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2013-09-09 — choose a marketed DIN from the same-category list.

Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2013-09-09 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Hexalen · DIN 02126230 Manufacturer: Eli Lilly Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2013-09-09 · brand HEXALEN · ATC L01XX03 ALTRETAMINE · form Capsule · route Oral · ingredients ALTRETAMINE 50 MG · company Eisai inc · schedule Prescription

Check this DIN again · Health Canada product record

Hexalen: Formulary list price $3.3600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.3600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18669 · Verify on the e-Formulary ↗ (DIN 02126230)

Source record

DIN 02126230: Hexalen Raw flags: sec3=Y Item: 100000095; group id 143; item number 0242; lccId None; manufacturer id LIL Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $3.3600; ministry $3.3600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02126230 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18669

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02126230

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2013-09-09 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

What the Health Canada label says it is for

Product monograph unavailable: no marketed product found